Business·Industry

Genexine, Inc.: How Long Can It Keep Selling Assets to Stay Afloat?…Debt Alone Totals 105.4 Billion Won

KIM SAE-MI
2026-11-19 10:32:02
[Edaily Reporter KIM SAE-MI ] Genexine, Inc.(095700)is securing the cash needed for research and development and operations by disposing of its financial assets, but its debt and interest burden remain significant.

Genexine, Inc.’s Magok Building 1 (Photo: ReporterKIM SAE-MI )

As of the end of September this year, Genexine, Inc.’s cash and cash equivalents totaled only 15.3 billion won, while its debt stood at 105.4 billion won. Although the company is refinancing the loan used to construct its Magok Research and Development (R&D) Center to manage maturity obligations, cash outflows continue, making it difficult to rule out the possibility of additional fundraising.
15
.
3 Billion Won in Cash vs. 105.4 Billion Won in Debt… Selling Assets to Cover Operating Expenses
According to Genexine, Inc.’s third-quarter report released on the 18th, cash and cash equivalents (including 5 billion won in short-term financial instruments) totaled just 15.3 billion won as of the end of September. During the same period, borrowings from financial institutions totaled 105.4 billion won, comprising 101.8 billion won in short-term debt and 3.6 billion won in long-term debt. This means that borrowings are 6.9 times the amount of cash and cash equivalents.

Short-term liquidity indicators are also tight. While current assets total 26.4 billion won, current liabilities amount to 127.3 billion won—meaning liabilities due within one year exceed current assets by 100.9 billion won. This structure makes extending maturities, refinancing, and securing additional funds critical.

The problem is that Genexine, Inc. is not generating sufficient cash from its core business. Genexine, Inc.’s cumulative revenue for the first three quarters was 5.6 billion won, but its operating loss reached 26.6 billion won. The cumulative net loss stood at 51.7 billion won, a 310% surge compared to the 12.6 billion won recorded in the same period last year. Equity fell by 28.9%, from 246.8 billion won at the end of last year to 175.4 billion won at the end of September this year.

Cash flow has also deteriorated. Genexine, Inc.’s cash flow from operating activities for the first three quarters of this year totaled minus (-) 19.7 billion won. This means the company is unable to cover the cash required for R&D and operations through operating activities alone.

Genexine, Inc. is liquidating its investment assets to cover the shortfall in operating funds. During the same period, net cash inflows from investing activities totaled 15.3 billion won, and net cash inflows from financing activities totaled 5.7 billion won, offsetting the cash outflows from operating activities. In particular, cash secured through the disposal of financial assets alone amounted to 21.6 billion won.

However, the value of its investment assets is also declining. The book value of Genexine, Inc.’s investments in affiliates decreased by 21.7%, from 113.9 billion won at the end of last year to 89.2 billion won at the end of September this year. In particular, the company recognized a cumulative impairment loss of 10.1 billion won this year on its investment in ToolGen Incorporated(199800). Equity method losses from all affiliates totaled 3.4 billion won.

External fundraising has also been rocky. Genexine, Inc. decided on the 16th of last month to conduct a third-party private placement worth 3 billion won with Korea Quantum iA, Inc., but withdrew the plan on the 26th of the same month. This was because the allottee failed to pay the subscription price by the deadline.

Interest Expenses Exceed Revenue… Completed Magok Office Building 2 Stands Vacant
Interest expenses are a particularly burdensome issue. Genexine, Inc.’s cumulative interest expenses for the first three quarters of this year totaled 6 billion won, 3.9 times the 1.5 billion won recorded in the same period last year. In effect, interest expenses exceeded cumulative revenue for the year.

One of the main causes of the interest burden is the Magok project financing (PF) loan. As of the end of September, the interest rate on the existing Magok PF loan ranged from 8% to 11% per annum. On the 2nd, Genexine, Inc. decided to refinance 41.4 billion won in existing debt related to the Magok PF. The collateral value provided to financial institutions is approximately 53.9 billion won, and the collateral period runs from the 6th of this month through November 5 of next year.

The Magok Phase 2 R&D Center (Magok Building 2), completed this year (Photo: ReporterKIM SAE-MI )

Securing rental income from the Magok Phase 2 R&D Center (Magok Building 2), which was completed this year, is also taking longer than expected. Although Magok Building 2 was reclassified as an investment property worth 46.4 billion won during the third quarter of this year, it has not yet generated any rental income. Choi Jae-hyun, CEO of Genexine, Inc., noted, “The second building remains vacant at this time.”

However, the resale restriction on the existing Magok building (Magok Building 1) is expected to be lifted by the first half of next year. Previously, Hong Seong-jun, CEO of Genexine, Inc., had outlined a plan during a shareholder meeting last October to secure 100 billion won in cash by selling Magok Building 1. Although Magok Building 1 was subject to a five-year resale restriction, it will become available for sale starting early next year.

There is also speculation that if the asset sales fall through or are delayed, additional fundraising will be unavoidable. With cash outflows from operating activities continuing and the burden of debt repayment piling up, it is difficult to rule out the possibility of external fundraising, such as a rights offering. The company maintains that it will secure operating funds primarily through the sale of its assets.

A Genexine, Inc. official stated, “Genexine, Inc.’s financial situation is not exactly comfortable. We are continuing to work on selling the buildings we currently own and our stakes in other companies. Some of these deals have already reached a fairly concrete stage.” The official added, “Once all these sales are completed, we will be able to secure the minimum necessary operating funds without having to resort to a rights offering or other financing.”

Economy

Corporation

IT·Science

Economy

Genexine, Inc.: How Long Can It Keep Selling Assets to Stay Afloat?…Debt Alone Totals 105.4 Billion Won

Genexine, Inc.(095700)is securing the cash needed for research and development and operations by disposing of its financial assets, but its debt and interest burden remain significant. Genexine, In…
2026-11-19 10:32:02

Corporation

After Enhancing the Flavor and Adding Protein… TakeFit Sees Sales Jump 48%

NamyangDairyProducts(003920)’s protein brand “TakeFit” saw its cumulative sales for the third quarter of this year increase by 48.3% compared to the same period last year. Analysts attribute this grow…
2026-11-19 09:14:40

IT·Science

Tickets to the Music Festival, a 2-Month Google AI Subscription, Roaming Discounts… SKT Rolls Out a Flurry of Benefits for Students Preparing for Exams

SK Telecom (SKTelecom(017670)) announced on the 19th that it will offer customized benefits—including cultural activities, artificial intelligence (AI) services, and roaming discounts—to customers who…
2026-11-19 10:46:01